Jump to content

Haloperidol: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Reverted edits by 203.6.146.5 (talk) to last revision by ClueBot NG (HG)
Line 71: Line 71:
</ref> It was developed in 1958 at the Belgian company [[Janssen Pharmaceutica]] and submitted to the first of clinical trials in [[Belgium]] later that year.<ref>{{cite journal |doi=10.1080/10401230591002048 |title=The Haloperidol Story |year=2005 |last1=Granger |first1=Bernard |last2=Albu |first2=Simona |journal=Annals of Clinical Psychiatry |volume=17 |issue=3 |pages=137–40 |pmid=16433054}}</ref>
</ref> It was developed in 1958 at the Belgian company [[Janssen Pharmaceutica]] and submitted to the first of clinical trials in [[Belgium]] later that year.<ref>{{cite journal |doi=10.1080/10401230591002048 |title=The Haloperidol Story |year=2005 |last1=Granger |first1=Bernard |last2=Albu |first2=Simona |journal=Annals of Clinical Psychiatry |volume=17 |issue=3 |pages=137–40 |pmid=16433054}}</ref>


Haloperidol was approved by the [[U.S. Food and Drug Administration]] (FDA) on April 12, 1967; it was later marketed in the U.S. and other countries under the brand name Haldol by [[McNeil Laboratories]].
Haloperidol was approved by a BUTT HEAD [[U.S. Food and Drug Administration]] (FDA) on April 12, 1967; it was later marketed in the U.S. and other countries under the brand name Haldol by [[McNeil Laboratories]].


==Pharmacology==
==Pharmacology==

Revision as of 05:19, 3 December 2012

Haloperidol
Clinical data
Trade namesHaldol
AHFS/Drugs.comMonograph
MedlinePlusa682180
Pregnancy
category
  • C
Routes of
administration		Oral, IM, IV, depot (as decanoate ester)
ATC code
Legal status
Legal status
  • US: WARNING[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityApprox. 50–60% (tablets and liquid)
Metabolismhepatic
Elimination half-life10–30 hours
ExcretionBiliary and renal
Identifiers
  • 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.142 Edit this at Wikidata
Chemical and physical data
FormulaC21H23ClFNO2
Molar mass375.9 g/mol g·mol−1
3D model (JSmol)
  • c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F
  • InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 checkY
  • Key:LNEPOXFFQSENCJ-UHFFFAOYSA-N checkY
  (verify)

Haloperidol is a dopamine antagonist of the typical antipsychotic class of medications. It is a butyrophenone derivative and has pharmacological effects similar to the phenothiazines.

Haloperidol is an older antipsychotic used in the treatment of schizophrenia and acute psychotic states and delirium. A long-acting decanoate ester is used as an injection given every four weeks to people with schizophrenia or related illnesses who have poor adherence to medication regimens and suffer frequent relapses of illness, or to overcome the drawbacks inherent to its orally administered counterpart that burst dosage increases risk or intensity of side effects. In some countries, such as the United States of America, injections of antipsychotics such as haloperidol can be ordered by a court at the request of a psychiatrist.

Haloperidol is sold under the tradenames Aloperidin, Bioperidolo, Brotopon, Dozic, Duraperidol (Germany), Einalon S, Eukystol, Haldol (common tradename in the US and UK), Halosten, Keselan, Linton, Peluces, Serenace, Serenase, and Sigaperidol.

History

Haloperidol was discovered by Paul Janssen.[2] It was developed in 1958 at the Belgian company Janssen Pharmaceutica and submitted to the first of clinical trials in Belgium later that year.[3]

Haloperidol was approved by a BUTT HEAD U.S. Food and Drug Administration (FDA) on April 12, 1967; it was later marketed in the U.S. and other countries under the brand name Haldol by McNeil Laboratories.

Pharmacology

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D2 receptor antagonism and slow receptor dissociation kinetics.[4] Haloperidol's negligible affinity for histamine H1 receptors and muscarinic M1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain and orthostatic hypotension though higher rates of treatment emergent extrapyramidal symptoms.

Haloperidol acts on the following receptors: (Ki)

Dopamine D1 (Silent antagonist) 10-15nM

Dopamine D5 (Silent antagonist) 15-17nM

Dopamine D2 (inverse agonist) 1.55nM[5]

Dopamine D3 (Inverse agonist) 0.74nM[6]

Dopamine D4 (inverse agonist) 5-9nM[7]

Sigma 1(Irreversible inactivation by HPP+): 3nM[8]

Sigma 2 agonist: 54nM[9]

5HT1A Agonist: 1927nM[10]

5HT2A (Silent antagonist) 53nM[10]

5HT2C (Silent antagonist) 10,000nM[10]

5HT6 (Silent antagonist) 3666nM[10]

5HT7 (Irreversible silent antagonist) 377.2nM[10]

Histamine H1 (Silent antagonist) 1800nM[10]

Muscarinic M1 (Silent antagonist) 10,000nM[10]

Alpha Adrenergic 1a (Silent antagonist) 12nM[10]

Alpha Adrenergic 2a (Silent antagonist) 1130nM[10]

Alpha Adrenergic 2b (Silent antagonist) 480nM[10]

Alpha Adrenergic 2c (Silent antagonist) 550nM[10]

NR1\NR2B Subunit containing NMDA receptor antagonist (Ifenprodil site): IC50 2mM[11]

Pharmacokinetics

Intramuscular injections

The drug is well and rapidly absorbed with a high bioavailability when injected intramuscularly. The decanoate injectable formulation is for intramuscular administration only and is not intended to be used intravenously. The plasma concentrations of haloperidol decanoate reach a peak at about six days after the injection, falling thereafter, with an approximate half-life of three weeks.[12]

Intravenous injections

The bioavailability is 100% in intravenous (IV) injection, and the very rapid onset of action is seen within seconds. The duration of action is four to six hours. If haloperidol is given as a slow IV infusion, the onset of action is slowed, and the duration of action is prolonged.

Haloperidol for injection

Therapeutic concentrations

Plasma levels of four to 25 micrograms per liter are required for therapeutic action. The determination of plasma levels can be used to calculate dose adjustments and to check compliance, particularly in long-term patients. Plasma levels in excess of the therapeutic range may lead to a higher incidence of side effects or even pose the risk of haloperidol intoxication.

The concentration of haloperidol in brain tissue is about 20-fold higher compared to blood levels. It is slowly eliminated from brain tissue,[13] which may explain the slow disappearance of side effects when the medication is stopped.[13][14]

Uses

A comprehensive review of haloperidol has found it to be an effective agent in treatment of symptoms associated with schizophrenia.[15] It is also used in the control of the symptoms of:

Some weeks or even months of treatment may be needed before a remission of schizophrenia is evident.

In some clinics, the use of atypical neuroleptics (e.g., clozapine, risperidone, olanzapine, or ziprasidone) is, in general, preferred over haloperidol, because these drugs have an appreciably lower incidence of extrapyramidal side effects. Each of these drugs, however, has its own spectrum of potentially serious side effects (e.g., agranulocytosis with clozapine, weight gain with increased risk of diabetes and of stroke). Atypical neuroleptics are also much more expensive and have recently been the subject of increasing controversy regarding their efficacy in comparison to older products and their side effects.

Haloperidol was considered indispensable for treating psychiatric emergency situations,[18][19] although the newer atypical drugs have gained greater role in a number of situations as outlined in a series of consensus reviews published between 2001 and 2005.[15][20][21][22] It is enrolled in the World Health Organization List of Essential Medicines.

As is common with typical neuroleptics, haloperidol is by far more active against "positive" psychotic symptoms (delusions, hallucinations, etc.) than against "negative" symptoms (social withdrawal, etc.).

A multiple-year UK study by the Alzheimer's Research Trust suggested this drug and other neuroleptic antipsychotic drugs commonly given to Alzheimer's patients with mild behavioural problems often make their condition worse.[23] The study concluded that

For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status and by some measures improved functional and cognitive status. Neuroleptics may have some value in the maintenance treatment of more severe neuropsychiatric symptoms, but this possibility must be weighed against the unwanted effects of therapy. The current study helps to inform a clinical management strategy for current practice, but the considerable risks of maintenance therapy highlight the urgency of further work to find, develop, and implement safer and more effective treatment approaches for neuropsychiatric symptoms in people with AD.

Controversial nonmedical uses

See also: Punitive psychiatry in the Soviet Union

Soviet dissidents, including medical staff, have reported several times on the use of haloperidol in the Soviet Union for punitive purposes or simply to break the prisoners' wills.[24][25][26] Notable dissidents who were administered haloperidol as part of their court-ordered treatment were Sergei Kovalev and Leonid Plyushch.[27] The accounts Plyushch gave in the West, after he was allowed to leave the Soviet Union in 1976, were instrumental in triggering Western condemnation of Soviet practices at the World Psychiatric Association's 1977 meeting.[28] The use of haloperidol in the Soviet Union's psychiatric system was prevalent because it was one of the few psychotropic drugs produced in quantity in the USSR.[29]

Haloperidol has been used for its sedating effects during the deportations of immigrants by the United States Immigration and Customs Enforcement (ICE). During 2002-2008, federal immigration personnel used haloperidol to sedate 356 deportees. By 2008, following court challenges over the practice, it was given to only three detainees. Following lawsuits, U.S. officials changed the procedure so the drug is administered only by the recommendation of medical personnel and under court order.[30][31]

Contraindications

Absolute

  • Pre-existing coma, acute stroke
  • Severe intoxication with alcohol or other central depressant drugs
  • Known allergy against haloperidol or other butyrophenones or other drug ingredients
  • Known heart disease, when combined will tend towards cardiac arrest

Special caution needed

  • Pre-existing Parkinson's disease[32] or dementia with Lewy bodies
  • Patients at special risk for the development of QT prolongation (hypokalemia, concomitant use of other drugs causing QT prolongation)
  • Compromised liver function (as haloperidol is metabolized and eliminated mainly by the liver)
  • In patients with hyperthyreosis, the action of haloperidol is intensified and side effects are more likely.
  • IV injections: risk of hypotension or orthostatic collapse

Adverse effects

Haloperidol is noted for its strong early and late extrapyramidal side effects.[15] The risk of the face-disfiguring tardive dyskinesia is around 4% per year in younger patients. Other predisposing factors may be female gender, pre-existing affective disorder, and cerebral dysfunction. Akathisia often manifests itself with anxiety, dysphoria, and an inability to remain motionless.

Other side effects include dry mouth, lethargy, restlessness of akathisia, muscle stiffness or cramping, restlessness, tremors, Rabbit syndrome, and weight gain; side effects like these are more likely to occur when the drug is given in high doses and/or during long-term treatment. Depression, severe enough to result in suicide, is quite often seen during long-term treatment. Care should be taken to detect and treat depression early in course. Sometimes the change from haloperidol to a mildly potent neuroleptic (e.g., chlorprothixene or chlorpromazine), together with appropriate antidepressant therapy, does help. Sedative and anticholinergic side effects occur more frequently in the elderly. The likelihood of one's experiencing one or more of these side effects is quite high regardless of age and gender, especially with prolonged use.

Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include spasm of the neck muscles sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

The potentially fatal neuroleptic malignant syndrome (NMS) is a significant possible side effect. Haloperidol and fluphenazine cause NMS most often. NMS involves fever and other symptoms. Allergic and toxic side effects occur. Skin rash and photosensitivity both occur in fewer than 1% of patients. Children and adolescents are particularly sensitive to the early and late extrapyramidal side effects of haloperidol. It is not recommended to treat pediatric patients.

QT prolongation with sudden death is a rarely seen, but clinically significant, side effect. Likewise, the development of thromboembolic complications are also seen.

Haloperidol may have a negative impact on vigilance or decrease the ability of the patient to drive or operate a machine, particularly initially.

Haloperidol is not devoid of potential psychological dependence. However, due to the debilitating side effects, patients prescribed this drug have a high rate of noncompliance. The current recommendation is to pay close attention to the patient's experience, and taper or discontinue use if the patient has a high rate of dissatisfaction with treatment, as it may lead to dangerously rapid discontinuation.

Haloperidol has been shown to dramatically increase dopamine activity, up to 98%, in test subjects after two weeks on a "moderate to high" dose compared to chronic schizophrenics.[33] In another study, a live survey of a patient showed the person has 90% more dopamine receptors, of the D2 subtype, than before treatment with haloperidol.[33] The long-term effect of this is unknown, but the first study concludes this upregulation is positively associated with severe dyskinesias (more upregulation, more dyskinesia).

Some research studies have suggested effects of haloperidol on brain tissue. In a 2005 placebo-compared study of six macaques receiving haloperidol for up to 27 months, a significant brain volume change of about 10% and weight decreases were detected.[34] In later studies (2008) of the stored samples, the previously reported changes were attributed primarily to astrocyte and oligodendrocyte loss, with the neuron loss at about 5%, which was not statistically significant.[35] A study in 2011 of rats given haloperidol in doses comparable to clinical use for eight weeks found a reduction in brain cortex volume of 10–12%.[36]

In other studies, the use of potent antipsychotics has been associated with cognitive decline and permanent brain damage.[37]

Other considerations

During long-term treatment of chronic psychiatric disorders, the daily dose should be reduced to the lowest level needed for maintenance of remission. Sometimes, it may be indicated to terminate haloperidol treatment gradually.[38]

Other forms of therapy (psychotherapy, occupational therapy/ergotherapy, or social rehabilitation) should be instituted properly.

Pregnancy and lactation

Data from animal experiments indicate haloperidol is not teratogenic, but is embryotoxic in high doses. In humans, no controlled studies exist. Unconfirmed studies in pregnant women revealed possible damage to the fetus, although most of the women were exposed to multiple drugs during pregnancy. Following accepted general principles, haloperidol should be given during pregnancy only if the benefit to the mother clearly outweighs the potential fetal risk.[39]

Haloperidol, when given to lactating women, is found in significant amounts in their milk. Breastfed children sometimes show extrapyramidal symptoms. If the use of haloperidol during lactation seems indicated, the benefit for the mother should clearly outweigh the risk for the child, or breastfeeding should be stopped.

Carcinogenicity

In an unconfirmed study at the Buffalo Psychiatric Center, relative risks of breast cancer in inmates undergoing long-term treatment with haloperidol were 3.5 times higher than those of patients at the general hospital, and 9.5 times higher than the reported incidents in the general population.[40] These results need confirmation by larger studies, and so far, no statistically acceptable evidence has been found to associate long-term use of haloperidol with the potential for increased breast cancer risk in female patients.[citation needed]

Neurotoxic metabolites

Haloperidol has been shown to metabolize in murine,[41] and human[42] hepatocytes via CYP-3A4 to the neurotoxic pyridinium metabolites 4-(4-chlorophenyl)-1-(4-fluorophenyl)-4-oxobutylpyridinium(HPP+)and 4-(4-chlorophenyl)-1-(4-fluorophenyl)-4-hydroxybutylpyridinium (RHPP+).[43] HPP+ and RHPP+ are lipophilic and have elimination half lives of 67.3 hrs and 63.3 hrs, respectively.[44] HPP+ is a structural analog of the more widely known Parkinson’s producing neurotoxin MPP+ and its precursor MPTP. Unlike MPP+, HPP+ is not dependent on MAO-B for metabolism to toxic species and does not require functional dopamine transporter protein for intracellular uptake.[45]

Microdialysis studies were performed in the striatum, substantia nigra and cortex of conscious rats to compare the neurotoxic potential of 1-methyl-4-phenylpyridinium (MPP+) and HPP+ to dopaminergic and serotonergic neurons. HPP+ was a less potent neurotoxin than MPP+ to dopaminergic neurons and displayed equipotent serotonergic neurotoxicity.[46] Impairment of cortico-striatal mitochondrial complex I is pathognomic of MPP+ neurotoxicity and Parkinson's cellular dysfunction.[47][48] HPP+ is more potent than MPP+ at inhibiting murine mitochondrial complex I with an IC50 of 12mMol for HPP+ and 160mMol for MPP+.[46] Prolonged, high dose (2 & 5 mg\kg) administration of haloperidol in a murine model elevates striatal nitric oxide, TNF-a, and caspase-3.[49]

HPP+ and RHPP+ have been found in the brains of patients taking Haldol at autopsy.[50] A short term 6 week trial failed to find statistically significant correlation between HPP+, RHPP+ and extrapyramidal symptoms.[51] A long term retrospective study found a significant positive correlation between levels of HPP+ and severity of tardive dyskinesia.[52]

Interactions

  • Other central depressants (alcohol, tranquilizers, narcotics): actions and side effects of these drugs (sedation, respiratory depression) are increased. In particular, the doses of concomitantly used opioids for chronic pain can be reduced by 50%.
  • Methyldopa: increased risk of extrapyramidal side effects and other unwanted central effects
  • Levodopa: decreased action of levodopa
  • Tricyclic antidepressants: metabolism and elimination of tricyclics significantly decreased, increased toxicity noted (anticholinergic and cardiovascular side effects, lowering of seizure threshold)
  • Quinidine, buspirone, and fluoxetine: increased plasma levels of haloperidol, decrease haloperidol dose, if necessary
  • Carbamazepine, phenobarbital, and rifampicin: plasma levels of haloperidol significantly decreased, increase haloperidol dose, if necessary
  • lithium: rare cases of the following symptoms have been noted: encephalopathy, early and late extrapyramidal side effects, other neurologic symptoms, and coma.[53]
  • Guanethidine: antihypertensive action antagonized
  • Epinephrine: action antagonized, paradoxical decrease in blood pressure may result
  • Amphetamine and methylphenidate: counteracts increased action of norepinephrine and dopamine in patients with narcolepsy or ADD/ADHD

Doses

As directed by the physician, the dose needed depends on the condition to be treated, age, and weight of patient:

  • Acute problems: single doses of 1 to 5 mg (up to 10 mg) oral or IM, usually repeated every four to six hours, not exceeding an oral dose of 100 mg daily. Doses used for IV injection are usually 5 to 10 mg as a single dose; not exceeding 50 mg daily. The British National Formulary recommends a maximum daily dose of 30 mg total (IM and oral) with a maximum of 18 mg by the IM route.
PET imaging studies have suggested low doses are preferable. Clinical response was associated with at least 65% occupancy of D2 receptors, while greater than 72% was likely to cause hyperprolactinaemia and over 78% associated with extrapyramidal side effects. Doses of haloperidol greater than 5 mg increased the risk of side effects without improving efficacy.[54] Patients responded with doses under even 2 mg in first episode psychosis.[55]
  • Chronic conditions: 0.5 to 20 mg daily oral doses are recommended, rarely more. The lowest dose that maintains remission is employed.
  • Experimental doses: In resistant cases of psychosis, small studies with oral doses of up to 300 to 500 mg daily have been conducted (in most cases with an anticholinergic, anti-Parkinsonian drug (Biperiden, Benzatropine, etc.) to avoid severe early extrapyramidal side effects. These studies showed no superior results and led to severe side effects. Also, the frequency of otherwise unusual side effects (hypotension, QT-time prolongation, and serious cardiac arrhythmias) was dramatically increased. The clinical use of haloperidol in these doses is discouraged now and it is recommended to switch the patient gradually to a different neuroleptic (e.g., clozapine, olanzapine, aripiprazole).
  • Depot forms are also available; these are injected deeply IM at regular intervals. The depot forms are not suitable for initial treatment, but are suitable for patients who have demonstrated inconsistency with oral dosages.

Overdose

Experimental evidence from animal studies indicates the doses needed for acute poisoning are quite high in relation to therapeutic doses. Overdoses with depot injections are uncommon, because only certified personnel are legally permitted to administer them to patients.

Symptoms

Symptoms are usually due to exaggerated side effects. Most often encountered are:

Treatment

Treatment is merely symptomatic and involves intensive care with stabilization of vital functions. In early detected cases of oral overdose, induction of emesis, gastric lavage, and the use of activated charcoal can all be tried. Epinephrine is avoided for treatment of hypotension and shock, because its action might be reversed. In the case of a severe overdose, antidotes such as bromocryptine or ropinirole may be used to treat the extrapyramidal effects caused by haloperidol, acting as dopamine receptor agonists.

Prognosis

In general, the prognosis of overdose is good, and lasting damage is not known, provided the patient has survived the initial phase. An overdose of haloperidol can be fatal.[56]

Other formulations

Skeletal formula of haloperidol decanoate: The decanoate group is highlighted in blue.

The decanoate ester of haloperidol (haloperidol decanoate, trade names Haldol decanoate, Halomonth, Neoperidole) has a much longer duration of action, so is often used in people known to be noncompliant with oral medication. A dose of 25 to 250 mg is given by intramuscular injection once every two to four weeks.[57]

The IUPAC name of haloperidol decanoate is 4-(4-chlorophenyl)-1-1[4-(4-fluorophenyl)-4-oxobutyl]-4 piperidinyl decanoate.

Veterinary use

Haloperidol is also used on many different kinds of animals. It appears to be particularly successful when given to birds, e.g., a parrot that will otherwise continuously pluck its feathers out.[58]

Dose forms

  • Liquid: 2.0 and 10 mg/ml
  • Tablets: 0.5, 1.0, 2.0, 5.0, 10, and 20 mg
  • Injection: 5 mg (1 ml)
  • Depot injection forms
  • The original brand Haldol and many generics are available

See also

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Healy, David (1996). The psychopharmacologists. Vol. 1. London: Chapman and Hall. ISBN 978-1-86036-008-4.[page needed]
  3. ^ Granger, Bernard; Albu, Simona (2005). "The Haloperidol Story". Annals of Clinical Psychiatry. 17 (3): 137–40. doi:10.1080/10401230591002048. PMID 16433054.
  4. ^ Seeman, P; Tallerico, T (1998). "Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors". Molecular Psychiatry. 3 (2): 123–34. doi:10.1038/sj.mp.4000336. PMID 9577836.
  5. ^ Leysen, JE; Janssen, PM; Gommeren, W; Wynants, J; Pauwels, PJ; Janssen, PA (1992). "In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone". Molecular Pharmacology. 41 (3): 494–508. PMID 1372084.
  6. ^ Malmberg, Åsa; Mikaels, Åsa; Mohell, Nina (1998). "Agonist and Inverse Agonist Activity at the Dopamine D3 Receptor Measured by Guanosine 5′-[γ-Thio]Triphosphate-[35S] Binding". The Journal of Pharmacology and Experimental Therapeutics. 285 (1): 119–26. PMID 9536001.
  7. ^ Leysen, JE; Janssen, PM; Megens, AA; Schotte, A (1994). "Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity". The Journal of Clinical Psychiatry. 55 (Suppl): 5–12. PMID 7520908.
  8. ^ Cobos, Enrique J.; del Pozo, Esperanza; Baeyens, José M. (2007). "Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells". Journal of Neurochemistry. 102 (3): 812–25. doi:10.1111/j.1471-4159.2007.04533.x. PMID 17419803.
  9. ^ Colabufo, Nicolaantonio; Berardi, Francesco; Contino, Marialessandra; Niso, Mauro; Abate, Carmen; Perrone, Roberto; Tortorella, Vincenzo (2004). "Antiproliferative and cytotoxic effects of some σ2 agonists and σ1 antagonists in tumour cell lines". Naunyn-Schmiedeberg's Archives of Pharmacology. 370 (2): 106–13. doi:10.1007/s00210-004-0961-2. PMID 15322732.
  10. ^ a b c d e f g h i j k Kroeze, Wesley K; Hufeisen, Sandra J; Popadak, Beth A; Renock, Sean M; Steinberg, Seanna; Ernsberger, Paul; Jayathilake, Karu; Meltzer, Herbert Y; Roth, Bryan L (2003). "H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs". Neuropsychopharmacology. 28 (3): 519–26. doi:10.1038/sj.npp.1300027. PMID 12629531.
  11. ^ Ilyin, VI; Whittemore, ER; Guastella, J; Weber, E; Woodward, RM (1996). "Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol". Molecular Pharmacology. 50 (6): 1541–50. PMID 8967976.
  12. ^ "drugs.com".
  13. ^ a b Kornhuber, Johannes; Schultz, Andreas; Wiltfang, Jens; Meineke, Ingolf; Gleiter, Christoph H.; Zöchling, Robert; Boissl, Karl-Werner; Leblhuber, Friedrich; Riederer, Peter (1999). "Persistence of Haloperidol in Human Brain Tissue". The American Journal of Psychiatry. 156 (6): 885–90. PMID 10360127.
  14. ^ Kornhuber, Johannes; Wiltfang, Jens; Riederer, Peter; Bleich, Stefan (2006). "Neuroleptic drugs in the human brain: Clinical impact of persistence and region-specific distribution". European Archives of Psychiatry and Clinical Neuroscience. 256 (5): 274–80. doi:10.1007/s00406-006-0661-7. PMID 16788768.
  15. ^ a b c Irving, Claire B; Adams, Clive E; Lawrie, Stephen (2006). Irving, Claire B (ed.). "Haloperidol versus placebo for schizophrenia". Cochrane Database of Systematic Reviews (4): CD003082. doi:10.1002/14651858.CD003082.pub2. PMID 17054159.
  16. ^ Giannini, A. James; Underwood, Ned A.; Condon, Maggie (2000). "Acute Ketamine Intoxication Treated by Haloperidol". American Journal of Therapeutics. 7 (6): 389–91. doi:10.1097/00045391-200007060-00008. PMID 11304647.
  17. ^ Giannini, AJ; Eighan, MS; Loiselle, RH; Giannini, MC (1984). "Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis". Journal of clinical pharmacology. 24 (4): 202–4. PMID 6725621.
  18. ^ Cavanaugh, SV (1986). "Psychiatric emergencies". The Medical clinics of North America. 70 (5): 1185–202. PMID 3736271.
  19. ^ Currier, Glenn W. (2003). "The Controversy over 'Chemical Restraint' In Acute Care Psychiatry". Journal of Psychiatric Practice. 9 (1): 59–70. doi:10.1097/00131746-200301000-00006. PMID 15985915.
  20. ^ Allen, MH; Currier, GW; Hughes, DH; Reyes-Harde, M; Docherty, JP; Expert Consensus Panel for Behavioral Emergencies (2001). "The Expert Consensus Guideline Series. Treatment of behavioral emergencies". Postgraduate Medicine (Spec No): 1–88, quiz 89–90. PMID 11500996.
  21. ^ Allen, Michael H.; Currier, Glenn W.; Hughes, Douglas H.; Docherty, John P.; Carpenter, Daniel; Ross, Ruth (2003). "Treatment of Behavioral Emergencies: A Summary of the Expert Consensus Guidelines". Journal of Psychiatric Practice. 9 (1): 16–38. doi:10.1097/00131746-200301000-00004. PMID 15985913.
  22. ^ Allen, Michael H.; Currier, Glenn W.; Carpenter, Daniel; Ross, Ruth W.; Docherty, John P. (2005). "Introduction: Methods, Commentary, and Summary". Journal of Psychiatric Practice. 11: 5. doi:10.1097/00131746-200511001-00002.
  23. ^ Ballard, Clive; Lana, Marisa Margallo; Theodoulou, Megan; Douglas, Simon; McShane, Rupert; Jacoby, Robin; Kossakowski, Katja; Yu, Ly-Mee; Juszczak, Edmund (2008). Brayne, Carol (ed.). "A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)". PLoS Medicine. 5 (4): e76. doi:10.1371/journal.pmed.0050076. PMC 2276521. PMID 18384230. Neuroleptics provided no benefit for patients with mild behavioural problems, but were associated with a marked deterioration in verbal skills {{cite journal}}: Unknown parameter |laydate= ignored (help); Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)CS1 maint: unflagged free DOI (link)
  24. ^ Podrabinek, Aleksandr (1980). Punitive Medicine. Ann Arbor Mich.: Karoma Publishers. pp. 15–20. ISBN 0-89720-022-5.
  25. ^ Kosserev, I; Crawshaw, R (1994). "Medicine and the Gulag". BMJ. 309 (6970): 1726–30. doi:10.1136/bmj.309.6970.1726. PMC 2542687. PMID 7820004.
  26. ^ de Boer, S. P. (1982). Biographical Dictionary of Dissidents in the Soviet Union, 1956-1975. The Hague: Martinus Nijhoff Publishers. ISBN 90-247-2538-0. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)[page needed]
  27. ^ Wade, N. (1976). "Sergei Kovalev: Biologist Denied Due Process and Medical Care". Science. 194 (4265): 585–7. doi:10.1126/science.194.4265.585. PMID 17818411.
  28. ^ "Censuring the Soviets". TIME. CNN. 1977-09-12. Retrieved 2009-06-21.
  29. ^ The Children of Pavlov, TIME, Jun. 23, 1980
  30. ^ "Fewer US deportees being sedated for removal". Epilepsy.com. Associated Press. 2008-12-30. Retrieved 2009-06-21.
  31. ^ Solis, Dianne (2009-01-05). "U.S. cuts back on sedating deportees with Haldol". Seattle Times. Retrieved 2009-06-21.
  32. ^ Leentjens, Albert FG; Van Der Mast, Rose C (2005). "Delirium in elderly people: An update". Current Opinion in Psychiatry. 18 (3): 325–30. doi:10.1097/01.yco.0000165603.36671.97. PMID 16639157.
  33. ^ a b Silvestri, Simone; Seeman, Mary V.; Negrete, Juan-Carlos; Houle, Sylvain; Shammi, C.M.; Remington, Garry J.; Kapur, Shitij; Zipursky, Robert B.; Wilson, Alan A. (2000). "Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study". Psychopharmacology. 152 (2): 174–80. doi:10.1007/s002130000532. PMID 11057521.
  34. ^ Dorph-Petersen, Karl-Anton; Pierri, Joseph N; Perel, James M; Sun, Zhuoxin; Sampson, Allan R; Lewis, David A (2005). "The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys". Neuropsychopharmacology. 30 (9): 1649–61. doi:10.1038/sj.npp.1300710. PMID 15756305.
  35. ^ Konopaske, Glenn T.; Dorph-Petersen, Karl-Anton; Sweet, Robert A.; Pierri, Joseph N.; Zhang, Wei; Sampson, Allan R.; Lewis, David A. (2008). "Effect of Chronic Antipsychotic Exposure on Astrocyte and Oligodendrocyte Numbers in Macaque Monkeys". Biological Psychiatry. 63 (8): 759–65. doi:10.1016/j.biopsych.2007.08.018. PMC 2386415. PMID 17945195.
  36. ^ Vernon, Anthony C.; Natesan, Sridhar; Modo, Mike; Kapur, Shitij (2011). "Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation". Biological Psychiatry. 69 (10): 936–44. doi:10.1016/j.biopsych.2010.11.010. PMID 21195390.
  37. ^ Breggin, Peter R. (2007). "Neuroleptic-Induced Neurotoxicity, Brain Damage, Persistent Cognitive Deficits, Dementia, and Psychosis". Brain disabling treatments in psychiatry. Springer. pp. 85–114. ISBN 0-8261-2934-X. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
  38. ^ "Haloperidol at Chemeurope".
  39. ^ http://www.drugs.com/pro/haldol.html[full citation needed]
  40. ^ Halbreich, U; Shen, J; Panaro, V (1996). "Are chronic psychiatric patients at increased risk for developing breast cancer?". The American Journal of Psychiatry. 153 (4): 559–60. PMID 8599407.
  41. ^ Igarashi, K.; Kasuya, F.; Fukui, M.; Usuki, E.; Castagnoli, N. (1995). "Studies on the metabolism of haloperidol (HP): The role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP". Life Sciences. 57 (26): 2439–46. doi:10.1016/0024-3205(95)02240-5. PMID 8847965.
  42. ^ Usuki, Etsuko; Pearce, Robin; Parkinson, Andrew; Castagnoli, Neal (1996). "Studies on the Conversion of Haloperidol and Its Tetrahydropyridine Dehydration Product to Potentially Neurotoxic Pyridinium Metabolites by Human Liver Microsomes". Chemical Research in Toxicology. 9 (4): 800–6. doi:10.1021/tx960001y. PMID 8831826.
  43. ^ Avent, Kathryn M.; Devoss, J. J.; Gillam, Elizabeth M. J. (2006). "Cytochrome P450-Mediated Metabolism of Haloperidol and Reduced Haloperidol to Pyridinium Metabolites". Chemical Research in Toxicology. 19 (7): 914–20. doi:10.1021/tx0600090. PMID 16841959.
  44. ^ Avent, Kathryn M.; Riker, Richard R.; Fraser, Gilles L.; Van Der Schyf, Cornelis J.; Usuki, Etsuko; Pond, Susan M. (1997). "Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: Is HPTP an intermediate?". Life Sciences. 61 (24): 2383–90. doi:10.1016/S0024-3205(97)00955-7. PMID 9399630.
  45. ^ Kawashima, Hidekazu; Iida, Yasuhiko; Kitamura, Youji; Saji, Hideo (2004). "Binding of 4-(4-chlorophenyl)-1-\4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a metabolite of haloperidol, to synthetic melanin: Implications for the dopaminergic neurotoxicity of HPP+". Neurotoxicity Research. 6 (7–8): 535–42. doi:10.1007/BF03033449. PMID 15639785.
  46. ^ a b Rollema, H; Skolnik, M; d'Engelbronner, J; Igarashi, K; Usuki, E; Castagnoli Jr, N (1994). "MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies". The Journal of Pharmacology and Experimental Therapeutics. 268 (1): 380–7. PMID 8301579.
  47. ^ Mythri, Rajeswara Babu; Jagatha, Balusamy; Pradhan, Nityananda; Andersen, Julie; Bharath, M. M. Srinivas (2006). "Mitochondrial Complex I Inhibition in Parkinson's Disease: How Can Curcumin Protect Mitochondria?". Antioxidants & Redox Signaling. 9 (3): 399–408. doi:10.1089/ars.2007.9.ft-25. PMID 17184173.
  48. ^ Beal, M. Flint (2006). "Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease". Annals of the New York Academy of Sciences. 991: 120–31. doi:10.1111/j.1749-6632.2003.tb07470.x. PMID 12846981.
  49. ^ Bishnoi, Mahendra; Chopra, Kanwaljit; Kulkarni, Shrinivas K. (2008). "Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia". European Journal of Pharmacology. 590 (1–3): 241–5. doi:10.1016/j.ejphar.2008.06.033. PMID 18590723.
  50. ^ Eyles, Darryl W.; Avent, Kathryn M.; Stedman, Terry J.; Pond, Susan M. (1997). "Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem". Life Sciences. 60 (8): 529–34. doi:10.1016/S0024-3205(96)00656-X. PMID 9042387.
  51. ^ Ulrich, Sven; Neuhof, Sabine; Braun, Verena; Danos, Peter; Pester, Uwe; Hoy, Ludwig (2000). "Disposition of Haloperidol Pyridinium and Reduced Haloperidol Pyridinium in Schizophrenic Patients: No Relationship with Clinical Variables During Short-Term Treatment". Journal of Clinical Psychopharmacology. 20 (2): 210–9. doi:10.1097/00004714-200004000-00014. PMID 10770460.
  52. ^ Ulrich, S.; Sandmann, U.; Genz, A. (2005). "Serum Concentrations of Haloperidol Pyridinium Metabolites and the Relationship with Tardive Dyskinesia and Parkinsonism: A Cross-Section Study in Psychiatric Patients". Pharmacopsychiatry. 38 (4): 171–7. doi:10.1055/s-2005-871240. PMID 16025420.
  53. ^ Sandyk, R; Hurwitz, MD (1983). "Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases". South African medical journal. 64 (22): 875–6. PMID 6415823.
  54. ^ Oosthuizen, P.; Emsley, R. A.; Turner, J.; Keyter, N. (2001). "Determining the optimal dose of haloperidol in first-episode psychosis". Journal of Psychopharmacology. 15 (4): 251–5. doi:10.1177/026988110101500403. PMID 11769818.
  55. ^ Tauscher, Johannes; Kapur, Shitij (2001). "Choosing the Right Dose of Antipsychotics in Schizophrenia". CNS Drugs. 15 (9): 671–8. doi:10.2165/00023210-200115090-00001. PMID 11580306.
  56. ^ "Haloperidol at Drugs.com".
  57. ^ Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th edition (McGraw-Hill, 2001).[page needed]
  58. ^ "Veterinary:Avian at Lloyd Center Pharmacy".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Haloperidol&oldid=526127871"